Intellia Reports Positive Phase 2 Results For NTLA-2002, An Investigational CRISPR Gene Editing Therapy For Hereditary Angioedema; 50 mg Dose Shows Up To 81% Reduction In Attack Rates With 8 Of 11 Patients Attack-Free
Portfolio Pulse from Benzinga Newsdesk
Intellia Therapeutics has reported positive Phase 2 results for its CRISPR gene editing therapy, NTLA-2002, aimed at treating hereditary angioedema. The 50 mg dose showed up to an 81% reduction in attack rates, with 8 out of 11 patients being attack-free. The data has been published in The New England Journal of Medicine and will be presented at the 2024 ACAAI Meeting. Screening for the Phase 3 HAELO study is currently underway.
October 24, 2024 | 12:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Intellia Therapeutics' NTLA-2002 shows promising Phase 2 results for hereditary angioedema, with significant reduction in attack rates. This could positively impact the stock as the therapy progresses to Phase 3 trials.
The positive Phase 2 results for NTLA-2002, showing significant reduction in attack rates, are likely to boost investor confidence in Intellia Therapeutics. The progression to Phase 3 trials indicates potential for future success and market approval, which could drive the stock price up.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100